Everolimus improved renal function without reducing the size of a kidney angiomyolipoma in a patient with tuberous sclerosis complex: A case report

被引：0

作者：

Ashida A. ^{[1
]}

Matsumura H. ^{[1
]}

Fujii Y. ^{[1
]}

Nakakura H. ^{[2
]}

Shirasu A. ^{[3
]}

Tamai H. ^{[1
]}

机构：

[1] Department of Pediatrics, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka

[2] Blood Purification Center, Arisawa General Hospital, 12-14 Higashinomachi, Hirakata City, Nakamiya, Osaka

[3] Department of Pediatrics, Hirakata City Hospital, 2-14-1 Kinyahonmachi, Hirakata City, Osaka

来源：

Renal Replacement Therapy | / 4卷 / 1期

关键词：

Angiomyolipoma; Everolimus; Glomerular hyperfiltration; mTOR inhibitor; Tuberous sclerosis complex;

D O I：

10.1186/s41100-018-0166-7

中图分类号：

学科分类号：

摘要：

Background: Tuberous sclerosis complex is an autosomal dominant genetic disorder that affects multiple organ systems and can result in tumors in the brain, skin, heart, and kidneys; it may also cause neurological symptoms. About 1 to 7% of patients develop end-stage renal disease due to bilateral renal angiomyolipoma. We herein describe a patient with a bilateral large kidney angiomyolipoma whose residual renal function was temporarily improved with everolimus treatment. Case presentation: A 39-year-old man was diagnosed with tuberous sclerosis complex associated with an angiomyolipoma that was first detected at 12 years of age and had enlarged to a size that completely filled the bilateral kidneys. Although his kidney function was poor at the start of everolimus treatment as indicated by a creatinine-based estimated glomerular filtration rate of 13.7 mL/min/1.73 m2, his kidney function recovered with an annual increase in the glomerular filtration rate of 4.57 mL/min/1.73 m2 without morphological changes or a reduction in the size of the angiomyolipoma after everolimus treatment. As a result, we were able to delay the initiation of renal replacement therapy for more than 1 year. Conclusions: Even in patients with tuberous sclerosis complex who exhibit decreased renal function, everolimus treatment can retain the renal function and delay introduction of dialysis without a reduction in the size of the renal angiomyolipoma. The pathophysiological mechanisms for the deterioration of renal function in patients with tuberous sclerosis complex may not involve renal parenchymal loss secondary to angiomyolipoma growth only but may also involve other mechanisms including glomerular hypertrophy and hyperfiltration associated with mTOR complex 1 overactivity. © 2018 The Author(s).

引用

共 16 条

[1]

Ejikemans M.J.C., Van Der War W., Rejinders L.J., Roes K.C.B., Van Waalwijk Van Doom-Khosrovani S.B., Pelletier C., Magestro M., Zonnenberg B., Long-Term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: An observational study in tuberous sclerosis complex patients in the Netherlands, Am J Kidney Dis, 66, pp. 638-645, (2015)

[2]

Vekeman F., Magestro M., Karner P., Duh M.S., Nichols T., Van Waalwijk Van Doorn-Khosrovani S.B., Zonnenberg B.A., Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs, J Med Economics, 18, pp. 1060-1070, (2015)

[3]

Bissler J.J., Kingswood J.C., Optimal treatment of tuberous sclerosis complex associated renal angiomyolipoma: A systematic review, Ther Adv Urol, 8, pp. 279-290, (2016)

[4]

Decleves A.E., Sharma K., Novel targets of antifibrotic and anti-inflammatory treatment in CKD, Nat Rev Nephrol, 10, pp. 257-267, (2014)

[5]

Martin K.R., Zhou W., Bowman M.J., Shih J., Au K.S., Dittenhafer-Reed K.E., Sisson K.A., Koeman J., Weisenberger D.J., Cottingham S.L., Deroos S.T., Devinski O., Winn M.E., Cherniak A.D., Shen H., Northrup H., Krueger D.A., Mackeigan J.P., The genomic landscape of tuberous sclerosis complex, Nat Commun, (2017)

[6]

Henske E.P., Jozwiak S., Kingswood J.C., Sampson J.R., Thiele E.A., Tuberous sclerosis complex, Nat Rev Disease Primers, (2016)

[7]

Wong H.T., McCartney D.L., Lewis J.C., Sampson J.R., Howe C.J., De Vries P.J., Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins, J Med Genet, 52, pp. 815-822, (2015)

[8]

Van Eeghen A.M., Black M.E., Pulsifer M.B., Kwiatkowski D.J., Thiele E.A., Genotype and cognitive phenotype of patients with tuberous sclerosis complex, Eur J Hum Genet, 20, pp. 510-515, (2012)

[9]

Van Eeghen A.M., Nellist A., Van Eeghen E.E., Thiele E.A., Central TSC2 missense mutations are associated with a reduced risk of infantile spasms, Epilepsy Res, 103, pp. 83-87, (2013)

[10]

Bissler J.J., Kingswood J.C., Radzikowska E., Zonnenberg B.A., Frost M., Belousova E., Sauter M., Nonomura N., Brakemeier S., De Vries P.J., Whittemore V.H., Chen D., Sahmoud T., Shah G., Lincy J., Lebwohl D., Budde K., Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicenter, randomized, double-blind, placebo-controlled trial, Lancet, 381, pp. 817-824, (2013)

← 1 2 →